ProCE Banner Activity

CE / CME

Tailor-Made: Individualizing Type 2 Diabetes Management with GLP-1 Receptor Agonists

Virtual Lecture

This on-demand webcast features expert commentary and Q&A from a leading endocrinologist and cardiologist. Learn about the role of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes (T2D), including recommendations, clinical evidence for glycemic, cardiovascular, and renal benefits, management of adverse events, and educating patients on appropriate use.

In Collaboration With The Academy of Physician Associates in Cardiology (APAC) and The American Society of Endocrine Physician Assistants (ASEPA)

Registered Nurses: 1.50 Nursing contact hours, includes 1.50 hour of pharmacology credit Physician Assistants: maximum of 1.50 hours of AAPA Category 1 CME credits

Released: July 15, 2022

Expiration: July 14, 2023

Begin Activity

Share

Faculty

Maria Argoud

Maria Argoud, PA-C

Physician Assistant
San Diego Coastal Endocrinology
San Diego, California

Darren K. McGuire

Darren K. McGuire, MD, MHSc, FACC

Distinguished Teaching Professor of Medicine
Division of Cardiology
Department of Internal Medicine
University of Texas Southwestern Medical Center
Dallas, Texas

Richard E. Pratley

Richard E. Pratley, MD

Adjunct Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, Maryland
Samuel E. Crockett Chair in Diabetes Research
Medical Director
AdventHealth Diabetes Institute
Senior Investigator and Diabetes Program Lead
AdventHealth Translational Research Institute
Orlando, Florida

Laura Ross

Laura Ross, PA-C

Physician Assistant
Department of Cardiology
Park Nicollet Heart and Vascular Center Methodist Hospital
St. Louis Park, Minnesota

Acknowledgement

This activity is supported by an educational grant from Novo Nordisk.

Provided by

ProCE Banner

Target Audience

This program is intended for NPs and PAs who care for patients with T2D.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the mechanism and clinical utility of GLP-1 RA therapy in patients with T2D

  • Differentiate among the GLP-1 RAs based on their glycemic effects, weight loss, and cardiorenal risk reduction

  • Incorporate GLP-1 RAs as part of guideline-recommended care based on patients’ cardiovascular, renal, and other risk factors

  • Formulate strategies to prevent and minimize gastrointestinal adverse effects of GLP-1 RAs, including dose titration and counseling

Disclosure

All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Maria Argoud, PA-C: consultant/advisor/speaker: Zealand.

Darren K. McGuire, MD, MHSc: consultant: Afimmune, Applied Therapeutics, Bayer, Metavant; clinical trial leader: AstraZeneca, Esperion, Lexicon, Pfizer; consultant/clinical trial leader: Boehringer Ingelheim, CSL Behring, Lilly, Merck, Novo Nordisk, Sanofi.

Richard E. Pratley, MD: researcher: Metavention, Poxel SA; consultant/advisor/speaker: Bayer, Corcept Therapeutics, Dexcom, Gasherbrum Bio, Hengrui USA, Merck, Pfizer, Rivus Pharmaceuticals, Sanofi, Scohia Pharma, Sun Pharmaceuticals; researcher/consultant/advisor/speaker: Hanmi Pharmaceuticals, Novo Nordisk.

Laura Ross, PA-C: has no relevant financial relationships to disclose.

None of the members of the Planning Committee or PCE staff have any financial relevant relationships to disclose.

CME Info

Participants wishing to earn CE/CME credit must:

  1. View the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete evaluation form

The estimated time to complete this activity is 1.50 hours.

Release date: July 15, 2022
Expiration date: July 14, 2023

Format

On-demand webcast

Disclaimer

The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.

Accreditation

PCE

Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

ANCC Credit Designation

NP Planner: Mary Knudtson, DNSc, NP, FAAN, University of California, Irvine, Irvine, California

Nursing contact hours: 1.50, which includes 1.50 hours of pharmacology credit

AAPA Credit Designation

Joint AccreditationPracticing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. Approval is valid until July 14, 2023. PAs should only claim credit commensurate with the extent of their participation.

PA course advisor: Amanda Zimmerman, PA-C, West Forsyth Pain Management, Winston-Salem, North Carolina

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 1.50 Interprofessional Continuing Education (IPCE) credits for learning and change.

Additional Information

Program Medium

This program has been made available online.